aspartate aminotransferase (40 U/l), and alanine aminotransferase (57 U/l) levels were significantly improved.
Pathological discussion: placenta
The physiological conversion of the decidual vessels of the lining of the endometrium to uteroplacental vessels is a unique transformation that does not occur in any other vessels. Through the process of implantation and dilatation, the uterine spiral arterioles, which are small muscular arteries, dilate into uteroplacental vessels with the destruction of the smooth muscle in the arteriolar wall. The end result is dilated uteroplacental vessels that do not respond to normal stimuli for vasoconstriction and remain open as conduits during pregnancy to supply blood to the fetus (Fig. 1) .
However, this patient_s placenta had extensive changes of malperfusion, hypoxia, and ischemia with lack of physiologic conversion of the decidua to uteroplacental tissue, thus resulting in a marked decidual vasculopathy. The smooth muscle walls of the arterioles remained and the ensuing small luminal area decreased the blood flow to the placenta (Fig. 2) . Other luminal changes that were seen as part of the decidual vasculopathy include fibrinoid necrosis of the vessel wall and decidual vascular thrombosis (Fig. 3) . Early ischemic changes included agglutination of the villi, meaning that these villi were no longer participating in maternal-fetal exchange (Fig. 4) .
As a normal pregnancy nears term, the remaining viable villi decrease in size so that there are more aggregates of syncytial nuclei called syncytial knots. At term, approximately 30% of the villi contain syncytial knots. However, in this placenta of approximately 21 weeks, there were more syncytial knots than expected, and the villi were smaller than expected for gestational age (Fig. 5 ). This accelerated maturity of the villi was a compensatory mechanism of the placenta to increase the surface area available for oxygen exchange in the face of hypoxia. Whereas some parts of the placenta attempted to compensate for the hypoxia, in other areas, chronic hypoxia caused inadequate growth and propagation of the villi, thus resulting in terminal villus deficiency. There was 25% infarction of the placenta, which is characteristic of preeclampsia and pregnancy-induced hypertension [1, 2] . However, when found to this degree in early pregnancy other underlying factors such as HELLP syndrome or antiphospholipid syndrome (APS) should be considered. Other conditions that could result in these placental pathological findings are inherited thrombophilias and SLE.
Clinical discussion: obstetrical
This patient_s presentation had a broadly differential diagnosis. Right upper quadrant tenderness during the second trimester of pregnancy may be because of hepatitis, pancreatitis, cholecystitis, or appendicitis. Hematemesis [7] .
may indicate severe gastritis, or if coupled with hematuria it could indicate either hemolytic uremic syndrome or thrombotic thrombocytopenic purpura. Because her ANA test was positive, SLE or another autoimmune disease was also a possibility. In this patient, the presence of preeclampsia with coexisting hemolysis, elevated liver function tests, and thrombocytopenia best corresponded with a diagnosis of HELLP syndrome. The HELLP syndrome is part of a spectrum of hypertensive disorders of pregnancy, including preeclampsia, pregnancy-induced hypertension, and acute fatty liver of pregnancy. Preeclampsia is defined by hypertension, proteinuria with or without nondependent edema, whereas eclampsia is preeclampsia with seizures. HELLP syndrome is often associated with severe preeclampsia and eclampsia, and is considered a hallmark of critical illness [3] . Table 3 shows the diagnostic criteria for HELLP syndrome. In addition to the liver involvement, HELLP syndrome may have varying degrees of brain or kidney end-organ involvement.
The pathophysiology of preeclampsia is still unknown, but is postulated to be because of an improper trophoblastic invasion of the maternal uterine myometrium secondary to a triggering event. This abnormal placentation leads to placental ischemia causing the release of toxic factors, which enter the systemic circulation and result in endothelial injury [4] . This intimal injury stimulates fibrin deposition, which in turn, causes platelets to release vasoconstrictive substances such as thromboxane A2, and causes more platelet aggregation [5] . Eventually, there can be enough fibrin deposition to cause obstruction of the liver sinusoids. This ultimately leads to hepatocellular sequelae and end-organ damage.
The presentation of HELLP syndrome may be nonspecific, as with this patient, and can range from flu-like symptoms to convulsions, or gastrointestinal hemorrhage. Fifteen percent of HELLP syndrome occurs in the second trimester. In preeclampsia, patients tend to be of younger age and closer to term. It is important to diagnose HELLP syndrome as early as possible to prevent fetal complications such as placental abruption, perinatal asphyxia, extreme maturity, growth restriction, intraventricular hemorrhage, and respiratory distress syndrome. Maternal complications include pulmonary edema, liver hematoma, retinal detachment, acute renal failure, disseminated intravascular coagulation, The treatment for severe preeclampsia and HELLP syndrome is immediate delivery, but unfortunately this patient_s fetus was below the age of viability, and a medical termination was necessary. Delivery does not always result in cure; approximately 25% of HELLP syndrome patients are diagnosed postpartum.
Clinical discussion: rheumatologic
The combination of severe preeclampsia, HELLP syndrome, and an arterial and venous thrombosis narrows the differential diagnosis to a thrombophilia, vasculitis, or APS. Although many of the acquired and inherited thrombophilias can result in preeclampsia, uteroplacental insufficiency, and venous thrombosis, only hyperhomocysteinemia or APS would account for an arterial thrombosis. In this patient, the homocysteine level was found to be normal. She had persistently positive anticardiolipin antibody (aCL); thus, in the presence of retinal artery and vein thrombosis, she met the clinical and laboratory criteria for primary APS [6, 7] . Marginally positive titers of ANA are not unusual in primary APS. A low C4 complement level, as seen in this patient, can be the result of severe preeclampsia.
This patient initially presented with both severe preeclampsia and HELLP syndrome. Severe preeclampsia is a recognized clinical manifestation of APS [8] , and it is included under the pregnancy morbidity criteria of the updated Sapporo APS classification criteria ( Table 4 ). The connection between HELLP syndrome and APS is not clearly indicated in the literature. A retrospective study by Le Thi Thuong et al. [9] showed that HELLP syndrome may be the presenting manifestation of APS and that HELLP syndrome occurs at an earlier stage of gestation in APS than during a normal pregnancy. Another retrospective series of 75 pregnancies showed a 10.5% rate of APS in HELLP syndrome patients [10] .
The rate of pregnancy loss in untreated APS is 80-90% [11, 12] . Approximately 10-15% of healthy women with recurrent pregnancy losses have aPL [13] , therefore establishing that the correct cause of pregnancy morbidity is important to optimize management. Other etiologies of early pregnancy loss should be first excluded, even in the presence aPL because embryonic pregnancy losses are common in the general population. Antiphospholipid syndrome is recognized to be a major contributor to late pregnancy losses [14] . As pregnancy and the postpartum period are prothrombotic states, management should focus on the prevention of pregnancy morbidity and maternal thrombotic complications.
Although management of aPL-positive patients is controversial because of limited well-designed controlled trials, several points need to be emphasized [14] : (1) corticosteroids are not indicated in the management of Definite APS is present if at least one of the clinical criteria and one of the laboratory criteria are met. Classification of APS should be avoided if less than 12 weeks or more than 5 years separate the positive aPL test and the clinical manifestation. In studies of populations of patients who have more than one type of pregnancy morbidity, investigators are strongly encouraged to stratify groups of subjects according to a, b, or c above. ELISA=Enzyme-linked immunosorbent assay aPL-positive patients during pregnancy as they are associated with a high risk of complications such as gestational diabetes, amnionitis, and premature rupture of membranes; (2) aPL-related nongravid clinical manifestations represent a spectrum (asymptomatic, pregnancy morbidity only, vascular event, or catastrophic APS) and the management strategies during a pregnancy are different based on the position of aPL-positive patients on this spectrum; (3) LDA and prophylactic dose heparin are the standard therapy for patients fulfilling the updated Sapporo APS classification criteria based on pregnancy morbidity only; (4) LDA and therapeutic dose heparin are the standard therapy for patients fulfilling the updated Sapporo APS classification criteria based on a vascular event (this would be the case in the event of a subsequent pregnancy with this patient); and (5) LDA is usually given to asymptomatic medium-to-high titer aPL-positive patients during pregnancy, but there are no data to support this strategy (because pregnancy and the presence of aPL can be additive risk factors for vascular thrombosis, LDA therapy can be justified as it has minimal maternal or fetal side effects).
Immunological discussion
The exact mechanism by which aPL causes fetal loss is unknown, but it is believed to be mediated through abnormal placental function. In APS, decidual vasculopathy, as described in this patient, has been cited as an immediate cause of fetal loss by many investigations [15] ; however, normal physiologic changes of the spiral arteries have also been reported in APS patients [16] . Antiphospholipid syndrome is associated with placental vascular thrombosis, decidual necrosis, and placental infarction [17, 18] , as is seen in this patient_s placental specimen, as well as inflammatory changes. Thus, altered coagulation and thrombosis in the uteroplacental circulation contributed to this pregnancy loss. Antiphospholipid antibodies are known to trigger the activation of endothelial cells and platelets [19, 20] , but the pathogenic mechanisms leading to thrombosis and tissue injury are unclear.
Murine models demonstrate the direct pathogenic effect of aPL by the passive transfer of human immunoglobulin G (IgG) from high titer aPL positive patients_ sera into pregnant mice, which result in fetal loss and growth retardation [21] . Further studies in this experimental model have shown that inhibition of complement activation by preventing the cleavage of complement 3 (C3), using Crry-Ig (an exogenously administered inhibitor of C3 activation), reduces fetal loss and growth retardation to levels seen in control mice [21] . Furthermore, Crry-Ig prevents C3 deposition within the deciduae and C3-deficient mice are resistant to fetal injury induced by aPL [22] .
In a subsequent series of murine studies, APS induced by passive transfer of human aPL was prevented by treatment of mice with anti-C5 monoclonal antibodies and mice deficient in C5 were also protected. To distinguish the contribution of C5a-C5a receptor (C5aR) interaction from those of the membrane attack complex (C5b-9), mice deficient in C5aR and mice treated with C5aR antagonist peptide were also studied. Blockage of C5a-C5aR interaction preserved pregnancies. These studies suggest that the C5-C5a receptor interactions are the critical intermediates linking pathogenic aPL to fetal damage [23, 24] and they implicate complement blockade, specifically at the level of C5 or C5aR as a potential therapy for APS. Complement C5 monoclonal antibodies have been already utilized to treat other inflammatory conditions, and they could have a role in the prevention of fetal loss and pregnancy complications in APS.
Using pregnant APS mice, induced through passive transfer of human aPL, heparin has been shown to protect mice from aPL-induced pregnancy complications and prevent complement activation in vivo and in vitro. Interestingly, in the absence of a detectable anticoagulant effect, heparin still protects mice from aPL-induced pregnancy loss. Other anticoagulants, fondaparinux and hirudin, have not reduced the risk of aPL-induced pregnancy loss [25] .
Case presentation: long-term follow-up After 3 years of follow-up, the patient has remained anticoagulated with warfarin (international normalized ratio target 2.5-3.5), and she has not experienced any further thrombotic events. She has not regained vision in her left eye, and the optic disc remains pale. To date, she has had no further pregnancies. Although, the rate of thrombosis after the discontinuation of anticoagulation is high in APS patients [26] , there is debate as to whether lifelong anticoagulation is necessary in APS patients, where a thrombotic risk factor, such as pregnancy in this case, can be identified as the trigger for clinical manifestations. The patient has consistently high positive titers of aCL and anti-b 2 glycoprotein-I antibodies but has not developed any clinical manifestations of SLE.
Conclusion
Antiphospholipid syndrome should be considered in the differential diagnosis of HELLP syndrome. Placental vascular thrombosis and inflammation, mediated by complement activation, increase the risk of growth restriction and fetal loss in APS. In addition to its anticoagulant role, heparin also reduces the risk of aPL-related pregnancy morbidities through the inhibition of complement activation. The specific modulation of the C5-C5a receptor interactions in APS may prove to be a new therapy in the future.
